PitchSend

Investor Presentaiton

HANSIZHUANG Commercialization Highlights First-class Commercialization Efficiency 1.12B RMB 2023 Sales Per Capita¹ • · Outstanding Achievements Sales outperformed most of the competing PD-1/PD-L1 in China since its launch in 2021 Became the Tier-1 PD-1 /PD-L1 products in China in 2023 Industry Leading > 2M RMB Higher than all PD-1/PD-L1 products marketed 2023 1. Sales per capita = Product sales / # of salesforce 13 2. Henlius internal data in China during the same time period² O 2024 Henlius. Differentiation strategy to tackle challenges and win opportunities iiiii Challenges & opportunities NSCLC survival data read-out ESCC indication approved . • • • Differentiation Strategy Focus on SCLC (15-20% of total lung cancer patients) Actively tackle with challenges from newly launched SCLC products, and accurately interpret the research results Effectively promote messages of product advantages to keeping the leading position The superior survival data for sq NSCLC, especially the Chinese subgroup read-outs, increased physicians' recognition of HANSIZHUANG'S efficacy Establish marketing synergy in NSCLC & SCLC Conduct commercialization for the new indication by leveraging HANSIZHUANG's efficacy for ESCC patients with immuno-therapy advantages Deliver the concept of precise treatment for precise benefits to rapidly increase ESCC market share 2 Henlius

View entire presentation